Recruiting PHASE1 INTERVENTIONAL 6-arm NCT06131840

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

An Open-label Phase 1 Study to Investigate PF-08046050 (SGN-CEACAM5C) in Adults With Advanced Solid Tumors

Sponsor: Sanofi

Conditions Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Gastroesophageal Junction Adenocarcinoma Pancreatic Ductal Adenocarcinoma Small Cell Lung Carcinoma Stomach Neoplasms

Interventions 5-Fluorouracil (5-FU) Leucovorin (LV) Oxaliplatin PF-08046050 bevacizumab

Updated 21 times since 2023 Last updated: Mar 12, 2026 Started: Nov 20, 2023 Primary completion: Sep 12, 2029 Completion: Sep 12, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06131840, this PHASE1 trial focuses on Carcinoma, Non-Small-Cell Lung and Colorectal Neoplasms and remains actively recruiting participants. Sponsored by Sanofi, it has been updated 21 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

21 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE1
Jan 2026 — Mar 2026 [monthly]

Recruiting PHASE1
Oct 2025 — Jan 2026 [monthly]

Recruiting PHASE1
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE1
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1

▶ Show 16 earlier versions

Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE1
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE1
May 2025 — Jun 2025 [monthly]

Recruiting PHASE1
Mar 2025 — May 2025 [monthly]

Recruiting PHASE1
Dec 2024 — Mar 2025 [monthly]

Recruiting PHASE1
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE1

First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi
Seagen, a wholly owned subsidiary of Pfizer

Data source: Seagen Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Aurora, United States , Baltimore, United States , Barcelona, Spain , Boston, United States , Duarte, United States , Edinburgh, United Kingdom , Esplugues de Llobregat, Spain , Grand Rapids, United States , Houston, United States and 17 more locations